Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.46 |
| ▸ | MTOR | P42345 | 10/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3786325 | 0.81 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL9948701 | 0.78 | MTOR (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL3795141 | 0.75 | SMN1; SMN2 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL9948614 | 0.73 | MTOR (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL3711360 | 0.72 | MTOR (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| Trifluoroacetic Acid SCHEMBL3782649 | 0.72 | MTOR (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL3785561 | 0.70 | ACKR3 (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL18276400 | 0.67 | VCP (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL9948610 | 0.66 | MTOR (0.76) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL3789860 | 0.64 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | PIK3CD 8/4885PIK3CA 9/4885PIK3CB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.